U.S. prices for the world’s 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters. The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such […]
Between new approvals, new drug applications and research collaborations with other companies, most of the big news about Bristol-Myers Squibb in the past year has concerned the company’s newest immuno-oncologic drug.
A three-part transaction with Novartis is anticipated to transform the future shape of GlaxoSmithKline, making the company more balanced and providing better opportunity for broadly based sales growth.
J&J’s innovation strategy has created an industry-leading pipeline and a cycle of success that positions the company for continued growth.
The leaders at Lilly knew that revenue would be bottoming out last year; with several recent new product approvals and more brewing in the pipeline, things are looking up in Indianapolis.
While Merck’s product sales and financial performance have been less than impressive of late, the company’s pipeline is providing hope for the future.
Novartis has undergone a series of transactions that now concentrate the company on three leading divisions with innovation power and worldwide scale: pharmaceuticals, eye care and generics.
Although price restrictions and lowered reimbursements initially affected the company’s 2014 performance, Novo Nordisk reached one of its long-time pipeline goals with the resubmission and approval of Tresiba in the United States.
After the restructuring of its operations, one key divestment, the acquisition of Hospira and some encouraging pipeline advances, Pfizer executives believe the company is on track for a return to significant growth in the future.